Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases
- PMID: 17289032
- DOI: 10.1016/j.febslet.2007.01.051
Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases
Abstract
Circulating nucleic acids (CNA) are present in small amounts in the plasma of healthy individuals. However, increased levels of plasma CNA have been reported in a number of clinical disorders like cancer, stroke, trauma, myocardial infarction, autoimmune disorders, and pregnancy-associated complications. CNA has received special attention because of its potential application as a non-invasive, rapid and sensitive tool for molecular diagnosis and monitoring of acute pathologies and the prenatal diagnosis of fetal genetic diseases. This review throws light on the current status of blood CNA as a diagnostic marker and its potential as a powerful tool in the future.
Similar articles
-
Diagnostic developments involving cell-free (circulating) nucleic acids.Clin Chim Acta. 2006 Jan;363(1-2):187-96. doi: 10.1016/j.cccn.2005.05.048. Epub 2005 Aug 26. Clin Chim Acta. 2006. PMID: 16126188 Review.
-
Circulating nucleic acids in plasma and serum: recent developments.Ann N Y Acad Sci. 2006 Sep;1075:1-9. doi: 10.1196/annals.1368.001. Ann N Y Acad Sci. 2006. PMID: 17108186
-
Circulating nucleic acids in plasma and serum: past, present and future.Curr Opin Mol Ther. 2004 Jun;6(3):273-8. Curr Opin Mol Ther. 2004. PMID: 15264429 Review.
-
Circulating fetal DNA: its origin and diagnostic potential-a review.Placenta. 2004 Apr;25 Suppl A:S93-S101. doi: 10.1016/j.placenta.2004.01.005. Placenta. 2004. PMID: 15033315 Review.
-
Circulating tumour-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up?Lung Cancer. 2005 Jul;49(1):1-12. doi: 10.1016/j.lungcan.2004.12.008. Lung Cancer. 2005. PMID: 15949585 Review.
Cited by
-
Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Elife. 2023 Nov 6;12:e90198. doi: 10.7554/eLife.90198. Elife. 2023. PMID: 37929934 Free PMC article.
-
Evidence for the utility of cfDNA plasma concentrations to predict disease severity in COVID-19: a retrospective pilot study.PeerJ. 2023 Sep 18;11:e16072. doi: 10.7717/peerj.16072. eCollection 2023. PeerJ. 2023. PMID: 37744227 Free PMC article.
-
Efficacy of cell-free DNA as a diagnostic biomarker in breast cancer patients.Sci Rep. 2023 Sep 15;13(1):15347. doi: 10.1038/s41598-023-42726-6. Sci Rep. 2023. PMID: 37715016 Free PMC article.
-
Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice.Cancers (Basel). 2023 Aug 2;15(15):3930. doi: 10.3390/cancers15153930. Cancers (Basel). 2023. PMID: 37568746 Free PMC article. Review.
-
Potential predictive value of circulating tumor DNA (ctDNA) mutations for the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer.Front Genet. 2023 Mar 16;14:1125970. doi: 10.3389/fgene.2023.1125970. eCollection 2023. Front Genet. 2023. PMID: 37007962 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
